Antisynthetase syndrome

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Antisynthetase syndrome is an autoimmune myositis-spectrum condition defined by an antibody to an aminoacyl-tRNA synthetase plus a compatible phenotype, most importantly ILD, inflammatory myopathy, arthritis, Raynaud phenomenon, fever and mechanic hands. Anti-Jo-1 is the most familiar antibody, but PL-7, PL-12, EJ, OJ and others often present with lung-predominant disease. The full feature set may unfold over years, so a narrow muscle-only assessment misses clinically important cases.

Lung disease determines much of the serious risk. HRCT frequently shows NSIP, organising pneumonia or a mixed pattern, while UIP-like fibrosis occurs in some patients. Rapidly progressive inflammatory ILD may worsen over days to weeks, especially in overlap phenotypes. Respiratory infection is the closest and most dangerous mimic because glucocorticoid can temporarily reduce fever while accelerating pathogen growth. Obtain microbiology and consider bronchoscopy when it changes care without postponing life-saving respiratory support.

Myositis evaluation includes objective proximal and neck strength, functional tasks, CK and other enzymes, MRI, EMG or biopsy when needed. Normal CK does not exclude lung-predominant antisynthetase syndrome. Arthritis may resemble rheumatoid disease but is often non-erosive; RF and anti-CCP can coexist. Mechanic hands are rough, fissured hyperkeratosis along radial fingers, but occupational dermatitis is common and antibody testing requires the complete systemic context.

Treatment is individualised because randomised syndrome-specific evidence is limited. Significant ILD usually needs glucocorticoid with early mycophenolate, tacrolimus, rituximab, cyclophosphamide or another steroid-sparing agent. Physiotherapy and pulmonary rehabilitation follow stabilisation. Relapse is common during taper, so treatment duration and reduction are based on serial lung physiology and function, not antibody titre. Drug selection explicitly addresses opportunistic infection, vaccination, fertility, pregnancy, renal and liver function and previous cumulative toxicity.

Key points

Suspect antisynthetase syndrome when ILD clusters with inflammatory myopathy, non-erosive arthritis, Raynaud phenomenon, fever or hyperkeratotic fissured mechanic hands.
A patient need not show the full classic triad at presentation; lung disease may precede weakness and CK may remain normal, especially with non-Jo-1 antibodies.
Request an experienced myositis antibody panel when phenotype supports it and confirm surprising line-blot results because low-level isolated reactivity can be false.
At baseline obtain HRCT, spirometry, lung volumes and DLCO, oxygen assessment, CK and muscle function, ECG, echocardiographic risk assessment and swallowing review when indicated.
NSIP, organising pneumonia and mixed NSIP-organising patterns are common; HRCT pattern helps but does not distinguish immune activity from infection without clinical and microbiological synthesis.
For rapidly progressive ILD, admit and treat infection as a parallel possibility while using high-dose glucocorticoid plus an early specialist steroid-sparing agent rather than glucocorticoid alone.
Mycophenolate, tacrolimus, rituximab or cyclophosphamide are selected according to severity, prior treatment, kidney and liver function, infection and reproductive factors; much use is specialist and off-label.
Monitor FVC, DLCO, oxygen need, HRCT trajectory, strength, CK and swallowing separately; improved CK does not prove the lungs are controlled.
Provide Pneumocystis prophylaxis when the immunosuppressive combination and local risk threshold indicate it, and screen TB, hepatitis and vaccines before biologic therapy when time allows.
Plan pregnancy during stable disease on compatible treatment; mycophenolate, methotrexate and cyclophosphamide require pre-conception substitution, while tacrolimus and azathioprine may be compatible under specialist guidance.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Antisynthetase autoimmunity

Autoantibodies target aminoacyl-transfer-RNA synthetases, most commonly histidyl-tRNA synthetase Jo-1, within a genetically and environmentally susceptible immune system.

Lung and exposure interaction

Smoking, occupational inhalation and respiratory mucosal injury may influence antigen expression and phenotype, although no single exposure is necessary or sufficient.

Heterogeneous antibody subtypes

Jo-1, PL-7, PL-12, EJ, OJ and other antisynthetase antibodies associate with differing muscle and lung prominence, severity and relapse patterns.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Shared lung-muscle autoimmunity
Immune responses to synthetase antigens activate lymphocytes and innate pathways in lung, muscle, synovium and skin, producing a linked but variably expressed syndrome.
2
Inflammatory alveolar injury
Cellular inflammation and organising injury often create NSIP, organising-pneumonia or mixed HRCT patterns that may respond before irreversible fibrosis dominates.
3
Muscle-fibre inflammation
Inflammatory and sometimes necrotising muscle injury causes proximal weakness and enzyme release, but muscle disease may be absent or delayed when ILD dominates.
4
Relapse and fibrotic repair
Recurrent immune activity during taper can cause cumulative lung fibrosis, traction change and pulmonary vascular stress despite improvement in joints or CK.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Lung-predominant presentation

Cough, exertional breathlessness, crackles, restriction or gas-transfer loss can precede muscle weakness and may be the only initial organ manifestation.

Inflammatory myopathy

Subacute symmetrical proximal and neck weakness, elevated CK, muscle MRI oedema and dysphagia support muscle involvement, although enzymes can be normal.

Mechanic hands

Hyperkeratotic, fissured radial fingers and palms with rough lateral surfaces support antisynthetase disease after occupational and irritant dermatitis are considered.

Inflammatory arthritis

Symmetrical small-joint synovitis or episodic non-erosive polyarthritis may precede lung and muscle disease and can mimic rheumatoid arthritis.

Rapidly progressive ILDRed flag

Increasing oxygen need and bilateral ground-glass or organising change over days to weeks is an emergency despite modest CK or muscle findings.

Bulbar or ventilatory weaknessRed flag

Wet voice, choking, weak cough, orthopnoea or low supine vital capacity identifies aspiration and ventilatory risk beyond parenchymal ILD.

Red flags requiring action

Rapidly worsening dyspnoea, resting hypoxia, falling FVC or diffuse new HRCT change requires same-day assessment for ILD progression and infection.
Dysphagia, weak cough, low supine FVC or hypercapnia suggests bulbar or respiratory muscle involvement in addition to parenchymal lung disease.
Fever, neutropenia, oral candidiasis or new focal opacity during combined immunosuppression requires urgent opportunistic-infection assessment.
Chest pain, syncope, troponin rise or disproportionate DLCO loss requires evaluation for myocarditis, pulmonary embolism or pulmonary hypertension.
A hot joint with systemic illness needs aspiration and culture; inflammatory arthritis does not protect against septic arthritis.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Myositis antibody panelFirst step
Why
Identify an antisynthetase specificity and associated risk phenotype within compatible clinical disease.
Interpretation and limitations
Confirm unexpected low-level or multiple line-blot results with laboratory advice; antibody positivity without clinical features is not sufficient for diagnosis.
02
HRCT chest
Why
Define ILD pattern, extent, acute inflammatory change and established fibrosis.
Interpretation and limitations
NSIP and organising patterns are common but not specific; compare infection, oedema, aspiration and exposure history and discuss in an ILD multidisciplinary meeting.
03
FVC, lung volumes, DLCO and oxygen assessment
Why
Quantify respiratory severity, progression and response using repeatable physiological measures.
Interpretation and limitations
FVC decline supports progression, while DLCO also falls with pulmonary vascular disease, anaemia and emphysema; include exertional desaturation.
04
CK, aldolase, AST, ALT, LDH and muscle assessment
Why
Detect muscle injury and establish objective strength and functional baseline.
Interpretation and limitations
Normal enzymes do not exclude lung-predominant syndrome; evaluate weakness with MRI, EMG or biopsy when the mechanism remains uncertain.
05
Microbiology and bronchoalveolar lavage
Why
Exclude bacterial, viral, Pneumocystis, mycobacterial and fungal infection before or during escalation.
Interpretation and limitations
Select sampling from immune exposure and HRCT; a negative upper-airway sample cannot exclude lower-respiratory opportunistic infection.
06
ECG, troponin, NT-proBNP and echocardiography
Why
Assess myocarditis, arrhythmia, ventricular disease and pulmonary-hypertension probability.
Interpretation and limitations
Disproportionate symptoms or DLCO change may require cardiac MRI, CT pulmonary angiography or right-heart catheterisation after specialist review.
07
Pre-immunosuppression safety screen
Why
Reduce preventable infection and reproductive harm before multidrug or biologic treatment.
Interpretation and limitations
Check FBC, renal, liver, hepatitis, HIV and TB according to the proposed agent and risk, vaccination history, pregnancy and fertility goals.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Infection

Viral pneumonitis, Pneumocystis, bacterial pneumonia, mycobacteria and fungal disease can mimic ILD progression, particularly after glucocorticoid and multidrug immunosuppression.

Other connective-tissue ILD

Systemic sclerosis, rheumatoid arthritis, MDA5 dermatomyositis, Sjogren disease and mixed CTD produce overlapping NSIP or organising patterns with different extra-pulmonary clues.

Hypersensitivity or drug pneumonitis

Bird, mould and occupational antigens or medicines such as amiodarone and immune therapies can cause inflammatory lung disease with incidental autoantibody results.

Idiopathic inflammatory myopathy

Dermatomyositis, immune-mediated necrotising myopathy and inclusion-body myositis may cause weakness without a true antisynthetase antibody or characteristic lung-joint phenotype.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01Diagnostic sequenceConnect lung, muscle, joint and skinFirst stepUnexplained ILD or myositis accompanies mechanic hands, arthritis, Raynaud or fever.

1Document onset and tempo, occupational and medicine exposures, full skin and joint examination, objective strength, swallowing, cough and respiratory physiology.
2Request HRCT, PFT or DLCO, muscle enzymes and phenotype-led myositis antibodies, confirming discordant serology with the laboratory.
3Discuss lung imaging and pathology in an ILD-myositis multidisciplinary service and use MRI, EMG, biopsy or bronchoscopy for unresolved mechanism.

02Rapid ILD escalationTreat inflammation while excluding infectionEscalationRespiratory symptoms, oxygen or imaging deteriorates over days to weeks.

1Admit, support oxygenation, send early bacterial, viral, fungal and Pneumocystis testing and assess embolism, aspiration, oedema and respiratory muscle weakness.
2Give intravenous methylprednisolone for a strongly suspected severe inflammatory phenotype and add early specialist tacrolimus, cyclophosphamide, rituximab or other combination according to risk.
3EscalationReview response daily using oxygen, respiratory rate, FVC where feasible, imaging and infection results, escalating critical-care and transplant discussion when decline continues.

03Stable active diseaseUse a steroid-sparing lung planClinically meaningful ILD, myositis or arthritis is active without immediate respiratory failure.

1Start an appropriate oral glucocorticoid dose and introduce mycophenolate, tacrolimus, azathioprine or another specialist agent early to reduce cumulative exposure.
2Treat arthritis, Raynaud, reflux and aspiration separately and begin graded muscle and pulmonary rehabilitation once inflammation is stabilising.
3Set serial FVC, DLCO, oxygen, strength, CK and swallowing targets and taper only when the threatened organ remains controlled.

04Apparent relapseRecheck infection and mechanismBreathlessness, opacity or weakness returns during treatment or glucocorticoid taper.

1Review adherence, dose, drug interactions and exact taper and obtain microbiology before assuming immune relapse, particularly during combined immunosuppression.
2Repeat physiology, oxygen, muscle function, CK and focused HRCT and evaluate embolism, pulmonary hypertension, aspiration and fixed fibrosis.
3Intensify or switch immunosuppression only after the dominant active mechanism is defined, and add antifibrotic treatment only for an eligible progressive-fibrosis phenotype.

Key medicines and prescribing safety5 treatments · regimens, roles and cautions

Rapid suppression of inflammatory muscle, joint and lung disease, usually as one component of combination treatment.

Prednisolone

For active muscle or lung disease, specialists commonly start 0.5–1 mg/kg orally once daily, with lower exposure for milder disease and a documented taper once the steroid-sparing regimen takes effect.

Exclude or treat infection, monitor glucose, pressure, mood, eyes and bone and consider Pneumocystis prophylaxis from total immunosuppressive risk. Never stop prolonged therapy abruptly.

Common steroid-sparing treatment for antisynthetase ILD and associated muscle or skin activity.

Mycophenolate mofetil

Start 500 mg orally twice daily and increase every one to two weeks as tolerated toward 1–1.5 g twice daily under the specialist ILD protocol.

Monitor FBC, liver and renal function, infection and gastrointestinal toxicity. It is teratogenic and requires pregnancy exclusion, effective contraception and planned pre-conception substitution.

Calcineurin-inhibitor option for significant or refractory myositis-associated ILD, often combined with glucocorticoid and another agent.

Tacrolimus

A specialist regimen may start about 0.05–0.075 mg/kg/day orally in two divided doses, then adjust to the service trough target and response rather than a fixed dose.

Monitor trough, creatinine, potassium, magnesium, glucose, pressure, neurotoxicity and CYP3A interactions. It may be used in pregnancy under specialist monitoring, with dose and level changes expected.

B-cell depletion for selected severe or refractory antisynthetase ILD, myositis or arthritis.

Rituximab

A common off-label specialist course is 1,000 mg intravenously on days 1 and 15, with retreatment determined by lung or muscle response, immunoglobulins and infection risk.

Specialist off-label use requires hepatitis B and infection screening, vaccination planning, premedication and monitoring for infusion reaction, hypogammaglobulinaemia, late neutropenia and rare PML. Coordinate conception timing with rheumatology.

Prevents Pneumocystis jirovecii pneumonia during sufficiently intense or prolonged glucocorticoid and combination immunosuppression.

Co-trimoxazole Pneumocystis prophylaxis

When prophylaxis is indicated, a common adult regimen is 960 mg orally three times weekly or 480 mg once daily, adjusted for renal function and local protocol.

Check sulfonamide allergy, FBC, renal function and potassium; cytopenia, rash and interaction with methotrexate or warfarin matter. It is not automatic for every patient and reproductive advice is required.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Progressive respiratory failure

Rapid inflammatory lung injury or cumulative fibrosis reduces gas transfer, causes oxygen dependence and may lead to ventilation, transplant or death.

Pulmonary hypertension

Fibrotic vascular loss, hypoxia and occasional primary vascular disease increase pulmonary pressure and right-heart strain, worsening functional limitation.

Bulbar and muscle disability

Proximal, respiratory and swallowing weakness causes falls, aspiration, malnutrition, ineffective cough and impaired work or self-care.

Immunosuppression toxicity

Serious and opportunistic infection, cytopenia, renal or liver toxicity, diabetes, osteoporosis, infertility and teratogenicity arise from prolonged combination treatment.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

During active ILD repeat symptoms, oxygen, FVC and DLCO every one to three months initially and use HRCT when the clinical or physiological trajectory needs explanation.
Measure objective strength, function, CK and swallowing separately; improvement in one compartment must not conceal deterioration in another.
At each respiratory decline obtain early infection testing and review Pneumocystis prophylaxis, vaccination, exposure and immunoglobulins where relevant.
Follow agent-specific FBC, liver, renal, potassium, magnesium, trough, immunoglobulin and hepatitis or TB schedules and document treatment interruptions.
Monitor rehabilitation, oxygen need, weight, aspiration, reflux, pulmonary-hypertension signals, mood, work and caregiver burden.
Review fertility, contraception and pregnancy plans before mycophenolate, methotrexate, cyclophosphamide, rituximab or changes in tacrolimus exposure.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

The triad is often asynchronous

Lung, arthritis and myositis may appear years apart, so old swollen joints or Raynaud can make current ILD intelligible.

Normal CK does not protect lungs

Non-Jo-1 and lung-predominant disease can be severe while muscle enzymes and limb power remain near normal.

Mechanic hands are contextual

Fissured radial fingers support antisynthetase disease but irritant occupational dermatitis is common and needs the systemic cluster.

One HRCT pattern has many causes

Organising or NSIP change can reflect autoimmune inflammation, infection, aspiration or medicine injury, especially during immunosuppression.

Antibody titre is not a taper target

Lung physiology, oxygenation, imaging behaviour, strength and function determine response more reliably than serial synthetase-antibody level.

11Common pitfallsFrequent interpretation and management errors.

01
Excluding antisynthetase syndrome because weakness or CK elevation is absent at first ILD presentation.
02
Treating a low-level line-blot antibody as diagnostic without confirming a compatible phenotype or assay reliability.
03
Escalating glucocorticoid for new ground-glass opacity before sampling for opportunistic infection.
04
Following CK while omitting serial FVC, DLCO, oxygen and swallowing assessment.
05
Using prolonged glucocorticoid monotherapy for clinically significant ILD without an early steroid-sparing plan.
06
Allowing pregnancy on mycophenolate or methotrexate because the reproductive discussion focused only on cyclophosphamide.